Despite the remarkable success of ICBs in improving objective response rates in a subset of patients, it has been demonstrated that only ≤ 20–30% of tumor patients with NSCLC, RCC, and melanoma benefited from CTLA-4 or PD-1 blockade17,23,48–50. The gene discussed is CTLA4; the disease is renal cell carcinoma.